Medline Gets Buy Rating Post-IPO as Sales Grow 10.7%

Key Facts

1Seeking Alpha rated Medline (MDLN) a buy after its 2025 IPO, citing organic net sales growth of 10.7% YoY.

2Medline faces margin pressure from rising costs, volatile cash flows, and a high 37x forward earnings multiple.

In a move boosting investor confidence in the post-IPO healthcare sector, Medline (MDLN) received a buy rating from Seeking Alpha following its 2025 listing. The report noted organic net sales grew 10.7% year-over-year, driven by new customer contracts and international expansion, but cautioned about rising costs, volatile cash flows, and a high forward earnings multiple of 37x.

MDLN shares traded at $39.61 at the close on June 29, 2026, per market data. The rating comes amid growing interest in healthcare stocks after recent IPOs, though rising costs and inflation continue to pressure margins, despite Medline's investment-grade credit rating from Fitch.

Investors will focus on upcoming earnings to assess Medline's ability to sustain sales growth while managing costs. Monetary policy from the Federal Reserve and inflation data remain closely watched, as they affect valuations of high-growth equities like MDLN.